5-Amino-1MQ and Berberine Interaction: Monitor | Peptide Database

Join others researching Chonluten — share findings, ask questions, and learn from real experiences Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD. Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

FDA-approved for promoting weight regain following involuntary weight loss due to major surgery. Oxandrolone accelerates lean mass recovery and improves nitrogen balance during the recovery period. Extensively studied in severe burn patients, where oxandrolone reduces protein catabolism, accelerates wound healing, shortens hospital stays, and improves long-term lean body mass outcomes. Widely used in major burn centers. Effective for reversing muscle wasting and weight loss in patients with HIV/AIDS. Increases lean body mass and improves functional capacity in wasting syndrome. FDA-approved indication for weight recovery after chronic infections that result in significant involuntary weight loss. Counteracts catabolic effects of prolonged corticosteroid therapy by enhancing nitrogen retention and protein synthesis, helping preserve lean mass during necessary glucocorticoid treatment. FDA-approved for relief of bone pain accompanying osteoporosis. Increases bone mineral density and reduces pain scores in osteoporotic patients, particularly postmenopausal women. Used as adjunctive therapy with growth hormone in girls with Turner syndrome to improve final adult height. Clinical trials show additive benefit when combined with GH therapy. Promotes nitrogen retention and anti-catabolic effects during energy restriction, preserving lean tissue while facilitating fat loss. Commonly used during cutting phases. Increases muscular strength through enhanced protein synthesis and creatine phosphate regeneration, without the water retention associated with aromatizing compounds. Clinical studies have demonstrated selective reduction in abdominal and visceral adipose tissue with oxandrolone treatment, independent of total caloric intake changes.